IP-NFT Bonding Curves for Neglected Disease Research
Description
“Patents become tradable, decaying assets” Problem–Solution Fit Problem: Neglected tropical diseases (NTDs) have no market incentive for pharma. Patents sit unused. Solution: Researchers mint IP-NFTs representing a patent or discovery. A bonding curve allows anyone to buy shares in future royalties. But here’s the twist: If no drug reaches Phase II within 5 years, the IP becomes public domain and all buyers get proportional refund (from a funded reserve). Innovation Time-decaying IP exclusivity with a parachute refund — reduces risk for donors. Hybrid mechanism: Philanthropy + crypto trading. Market Viability TAM: $6B/year in NTD funding (Gates, WHO, USAID). They seek novel financing mechanisms. Early adopters: Social impact DAOs (e.g., VitaDAO, Molecule) already use IP-NFTs. Scalability Can spin up 100+ disease-specific bonding curves in parallel. Legal complexity is the bottleneck, but templates exist from Molecule. Feasibility High — existing tech (IP-NFTs on Ethereum + bonding curve contracts). Regulatory risk: Securities laws. Mitigate with non-transferable governance rights initially. Strengths Directly addresses your “neglected tropical diseases” need. Novel funding model (not just grants or tokens). Refund feature lowers donor anxiety. Next Step Partner with a university tech transfer office for an orphan drug patent — launch a bonding curve with a 3-year public domain clock.
This idea proposes utilizing IP-NFTs and bonding curves to incentivize research into neglected tropical diseases by turning patents into tradable, decaying assets with a refund mechanism. This hybrid philanthropic-crypto trading model aims to attract novel funding by reducing donor risk and leveraging existing blockchain technology.
Strengths
- •Addresses a clear market failure in neglected disease funding.
- •Innovative combination of philanthropic and market-based incentives with a unique refund mechanism.
- •Leverages existing IP-NFT and bonding curve technology for greater efficiency.
Risks
- •Significant regulatory hurdles concerning securities laws for the bonding curve and IP-NFTs.
- •Reliance on a "funded reserve" raises questions about sustainability and initial capitalization.
- •The 5-year Phase II milestone might be too short for complex drug development, leading to frequent refunds and potential loss of interest.
Next Steps
- •Secure legal counsel specializing in securities and intellectual property law to navigate regulatory complexities and define bonding curve parameters.
- •Develop a detailed financial model for the funded reserve, demonstrating its feasibility and identifying initial capital sources.
- •Pilot the concept with a single, well-defined orphan drug patent in partnership with a university tech transfer office and a supportive DAO to gather real-world data.